Key facts
- This page summarizes Greg Pyszczymuka's Form 3 filing for Evoke Pharma Inc (EVOK).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 24 Feb 2025, 17:00.
Greg Pyszczymuka - 20 Feb 2025 Form 3 Insider Report for Evoke Pharma Inc (EVOK)
- Reporting relationship
- Director
- Issuer ticker
- EVOK
- Reported as of
- 20 Feb 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 24 Feb 2025, 17:00:12 UTC
- Prior SEC filing
- 02 Jan 2025
- Next SEC filing
- 31 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew J. D'Onofrio, Attorney-in-fact for Greg Pyszczymuka
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Greg Pyszczymuka filed Form 3 for Evoke Pharma Inc (EVOK) on 24 Feb 2025.
Change
- Previous filing in this sequence was filed on 02 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EVOK
holding
No securities are beneficially owned.
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 20 Feb 2025
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
Exhibit 24 - Power of Attorney